Investors can contact the law firm at no cost to learn more about recovering their losses
LOS ANGELES, April 01, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Disc Medicine, Inc. (“Disc” or the “Company”) (NASDAQ: IRON) investors that the law firm has initiated an investigation on behalf of investors that lost money on their Disc stock. Disc investors are encouraged to contact the firm to discuss their legal rights.
Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: lesley@portnoylaw.com, to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
On April 1, 2024, Disc announced through a press release the primary findings from its Phase 2 AURORA Study of Bitopertin in patients with Erythropoietic Protoporphyria (EPP). Among the key points, the company highlighted that "although bitopertin showed a strong effect on the important secondary goal of cumulative light exposure time, in line with outcomes observed in the BEACON study, it did not achieve statistical significance because of a significantly large placebo effect." In the wake of this announcement, there was a downturn in the company's stock value.
Please visit our website to review more information and submit your transaction information.
The Portnoy Law Firm represents investors in pursuing claims caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.
Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
lesley@portnoylaw.com
310-692-8883
www.portnoylaw.com
Attorney Advertising
